Literature DB >> 16988230

Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.

O K Giddings1, C S Eickhoff, T J Smith, L A Bryant, D F Hoft.   

Abstract

Trypanosoma cruzi is a protozoan parasite that can initiate mucosal infection after conjunctival exposure. The anatomical route of T. cruzi invasion and spread after conjunctival parasite contamination remains poorly characterized. In the present work we have identified the sites of initial invasion and replication after contaminative conjunctival challenges with T. cruzi metacyclic trypomastigotes using a combination of immunohistochemical and real-time PCR confirmatory techniques in 56 mice between 3 and 14 days after challenge. Our results demonstrate that the predominant route of infection involves drainage of parasites through the nasolacrimal duct into the nasal cavity. Initial parasite invasion occurs within the ductal and respiratory epithelia. After successive waves of intracellular replication and cell-to-cell spread, parasites drain via local lymphatic channels to lymph nodes and then disseminate through the blood to distant tissues. This model of conjunctival challenge was used to identify immune responses associated with protection against mucosal infection. Preceding mucosal infection induces mucosal immunity, resulting in at least 50-fold reductions in recoverable tissue parasite DNA in immune mice compared to controls 10 days after conjunctival challenge (P < 0.05). Antigen-specific gamma interferon production by T cells was increased at least 100-fold in cells harvested from immune mice (P < 0.05). Mucosal secretions containing T. cruzi-specific secretory immunoglobulin A harvested from immune mice were shown to protect against mucosal parasite infection (P < 0.05), demonstrating that mucosal antibodies can play a role in T. cruzi immunity. This model provides an important tool for detailed studies of mucosal immunity necessary for the development of mucosal vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988230      PMCID: PMC1594886          DOI: 10.1128/IAI.00319-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Type 1 immunity provides optimal protection against both mucosal and systemic Trypanosoma cruzi challenges.

Authors:  D F Hoft; C S Eickhoff
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

Review 2.  Cell invasion by un-palatable parasites.

Authors:  L D Sibley; N W Andrews
Journal:  Traffic       Date:  2000-02       Impact factor: 6.215

3.  DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene.

Authors:  A E Fujimura; S S Kinoshita; V L Pereira-Chioccola; M M Rodrigues
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

4.  DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection.

Authors:  P Sepulveda; M Hontebeyrie; P Liegeard; A Mascilli; K A Norris
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi.

Authors:  D F Hoft; A R Schnapp; C S Eickhoff; S T Roodman
Journal:  Infect Immun       Date:  2000-01       Impact factor: 3.441

6.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  Involvement of Trypanosoma cruzi metacyclic trypomastigote surface molecule gp82 in adhesion to gastric mucin and invasion of epithelial cells.

Authors:  Ivan Neira; Fernando A Silva; Mauro Cortez; Nobuko Yoshida
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  Humoral and cellular immune responses to Trypanosoma cruzi-derived paraflagellar rod proteins in patients with Chagas' disease.

Authors:  Vladimir Michailowsky; Keith Luhrs; Manoel Otávio C Rocha; David Fouts; Ricardo T Gazzinelli; Jerry E Manning
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

9.  [The oral route: an access port for Trypanosoma cruzi].

Authors:  M L Calvo Méndez; B Nogueda Torres; R Alejandre Aguilar
Journal:  Rev Latinoam Microbiol       Date:  1992 Jan-Mar

10.  Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.

Authors:  Anita R Schnapp; Chris S Eickhoff; Donata Sizemore; Roy Curtiss; Daniel F Hoft
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more
  23 in total

Review 1.  Mechanisms of Trypanosoma cruzi persistence in Chagas disease.

Authors:  Fnu Nagajyothi; Fabiana S Machado; Barbara A Burleigh; Linda A Jelicks; Philipp E Scherer; Shankar Mukherjee; Michael P Lisanti; Louis M Weiss; Nisha J Garg; Herbert B Tanowitz
Journal:  Cell Microbiol       Date:  2012-02-24       Impact factor: 3.715

2.  Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; Xiuli Zhang; Olivia K Giddings; Thomas E Lane; Daniel F Hoft
Journal:  J Immunol       Date:  2011-06-29       Impact factor: 5.422

3.  ECG detection of murine chagasic cardiomyopathy.

Authors:  Christopher S Eickhoff; Cade T Lawrence; John E Sagartz; Leesa A Bryant; Arthur J Labovitz; Simil S Gala; Daniel F Hoft
Journal:  J Parasitol       Date:  2010-08       Impact factor: 1.276

4.  Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge.

Authors:  Matthew H Collins; Julie M Craft; Juan M Bustamante; Rick L Tarleton
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

5.  Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection.

Authors:  Christopher S Eickhoff; Olivia K Giddings; Nobuko Yoshida; Daniel F Hoft
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-08       Impact factor: 2.743

6.  Mice with Genetic Deletion of Group VIA Phospholipase A2β Exhibit Impaired Macrophage Function and Increased Parasite Load in Trypanosoma cruzi-Induced Myocarditis.

Authors:  Janhavi Sharma; Jennifer R Blase; Daniel F Hoft; John O Marentette; John Turk; Jane McHowat
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

7.  Deficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.

Authors:  Nicole L Sullivan; Christopher S Eickhoff; John Sagartz; Daniel F Hoft
Journal:  J Immunol       Date:  2015-01-16       Impact factor: 5.422

8.  Induction of proinflammatory cytokines and nitric oxide by Trypanosoma cruzi in renal cells.

Authors:  Gabriel M de Oliveira; Nobuko Yoshida; Elisa M S Higa; Sérgio Shenkman; Monique Alves; Daniela Staquicini; Cynthia Cascabulho; Nestor Schor
Journal:  Parasitol Res       Date:  2011-02-17       Impact factor: 2.289

Review 9.  CD8+ T cells in Trypanosoma cruzi infection.

Authors:  Angel M Padilla; Juan M Bustamante; Rick L Tarleton
Journal:  Curr Opin Immunol       Date:  2009-07-29       Impact factor: 7.486

10.  Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.

Authors:  O K Giddings; C S Eickhoff; N L Sullivan; D F Hoft
Journal:  Infect Immun       Date:  2010-01-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.